Homepage
Author:
AbbVie Inc.
Posted Date:
April 13, 2026
AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026
AbbVie Inc.
April 13, 2026
BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through “The Confidence Collective” for Fourth Year
AbbVie Inc.
April 8, 2026
Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin
AbbVie Inc.
April 7, 2026
/C O R R E C T I O N — AbbVie/
AbbVie Inc.
March 31, 2026
Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®
AbbVie Inc.
March 31, 2026
AbbVie to Host First-Quarter 2026 Earnings Conference Call
AbbVie Inc.
March 31, 2026
Allergan Aesthetics Releases Findings on the Safety and Efficacy of Repeat TrenibotE Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors at the 2026 American Academy of Dermatology Meeting (AAD)
AbbVie Inc.
March 30, 2026
AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting
AbbVie Inc.
March 27, 2026
Allergan Aesthetics Ushers in a New Age of Hyaluronic Acid (HA) Injectables with JUVÉDERM® at AMWC Monaco
AbbVie Inc.
March 26, 2026
Allergan Aesthetics Ushers in a New Age of Hyaluronic Acid (HA) Injectables with JUVÉDERM® at AMWC Monaco
AbbVie Inc.
March 26, 2026
1
2
3
Next
